Vitoria-Gasteiz, Spain, January 26th, 2024:
Geroa Diagnostics patented a Salivary Lactoferrin product for the diagnosis of Alzheimer´s Disease (AD) and associated Mild Cognitive Impairment (MCIAD). This product has been approved by INVIMA (National Institute for Food and Drug Surveillance) for its distribution in the Colombian market. This approval has been obtained by Annar Health Technologies, Geroa´s commercial partner for Colombia and several other Latin American Markets.
AD is a worldwide public health epidemic that will affect more than 139 million people by 2050. Over the same period of time, the cost of AD is expected to rise to more than 1.1 trillion USD$, in the US alone.
“This is a significant developmental milestone for our company and our team,” according to Bob Jenkins, CEO of Geroa. “Colombia is one of our key early markets, where we expect to show both traction in the market as well as significant clinical value centered on the cost effective and early diagnosis of a rapidly growing disease,” he continues. “We are working side-by-side with the ideal partner for our product in these market”.
Annar Health Technologies is a market leader in in-vitro diagnostics in Colombia and have a strong presence in other markets in LATAM covering broad range of segments. They are ideally placed to bring Geroa´s product to market and help governments, clinicians, patients, and carers of AD sufferers benefit from an early AD diagnosis in Latin America.
Michael Himmel, CEO of Annar Health Technologies, highlighted the fact that with the use of salivary biomarkers, patients can access a completely non-invasive and accessible biomarker compared to other diagnostic modalities, some of which, such a PET, are not available in Colombia.
About Geroa Diagnostics
Geroa Diagnostics is an early commercial phase human diagnostics Company based in Spain. We are centered on commercializing a proprietary patented diagnostic for Alzheimer´s disease. Our product has comparable analytical performance to current best practice (PET scans), but at a low cost. The test in saliva based and so, unlike PET scans, CSF testing or blood-based tests, is completely non-invasive.
About Annar Health Technologies
Annar is a reagent and medical device provider that offers custom-made solutions to their customers, such as: consulting service to improve the operation efficiency, lab software, point of care, quality control, blood bank, among others and data analysis modules, business intelligence, to a complete process of just in time delivery, with the most complete value proposition in the market based on innovation and flexibility. Annar generates an impact on health in a profitable and sustainable way.
For more information, please contact:
Bob Jenkins Hamley: CEO Geroa Diagnostics. +34 664 388 844; [email protected] Melanie Pinheiro: Business Development; +34 696 158 710 / +57 300 363 9539; [email protected]
For more information, please visit: www.geroadx.com
Leave A Comment